- Name: Lisa Anderson
- Age: 38 years
- Gender: Female
- Medical History: Diagnosed with acromegaly at age 32, pituitary adenoma was surgically removed, and she has been on somatostatin analogs for six years.
Lisa Anderson presented to her endocrinologist with ongoing symptoms of acromegaly, including facial changes, enlarged hands and feet, joint pain, and persistent headaches. Despite undergoing pituitary surgery and receiving somatostatin analog therapy, her symptoms had not been adequately controlled.
- Medical History and Imaging: Lisa’s medical history revealed a diagnosis of acromegaly due to a pituitary adenoma at age 32. She underwent transsphenoidal surgery to remove the tumor and has been receiving monthly injections of a somatostatin analog for six years. Imaging confirmed the absence of a residual tumor.
- Current Hormone Levels: Blood tests indicated elevated levels of insulin-like growth factor 1 (IGF-1) and growth hormone (GH), despite being on somatostatin analog therapy. Lisa’s levels were consistently above the upper limit of normal.
Given Lisa’s history of acromegaly and uncontrolled hormonal levels, her endocrinologist discussed various treatment options:
- Adjustment of Somatostatin Analog Therapy: The endocrinologist considered increasing the dosage or frequency of somatostatin analogs to further suppress GH and IGF-1 production. However, concerns were raised about potential side effects and the limited efficacy of this approach.
- Cholecystokinin (CCK) Therapy: Lisa’s endocrinologist introduced the possibility of CCK therapy as an adjunctive treatment to enhance GH and IGF-1 control. CCK could potentially stimulate hormonal pathways differently, improving symptom management.
Lisa decided to participate in a clinical trial exploring the use of CCK therapy as an additional treatment for acromegaly. Her treatment plan included:
- Baseline Assessment: A comprehensive evaluation of Lisa’s hormonal profile, including GH and IGF-1 levels, was conducted before initiating CCK therapy.
- CCK Administration: Lisa received subcutaneous CCK injections three times a week for six months, in addition to her ongoing somatostatin analog therapy.
- Monitoring: Throughout the treatment period, Lisa’s hormonal levels, physical symptoms, and overall quality of life were closely monitored. Any adverse effects or changes in hormonal levels were documented.
After six months of CCK therapy, Lisa experienced significant improvements in her acromegaly-related symptoms. Her facial features became less pronounced, and her joint pain and headaches were notably reduced. Laboratory results indicated a significant decrease in both GH and IGF-1 levels, which were now within the normal range.
Lisa’s case suggests that CCK therapy may have a role in enhancing hormonal control and improving symptom management in individuals with acromegaly, particularly in those with refractory symptoms despite standard therapies.
However, it is essential to acknowledge that further research, including larger clinical trials, is necessary to establish the safety, long-term efficacy, and optimal dosing of CCK therapy for acromegaly. Additionally, patient selection criteria and potential interactions with existing treatments should be carefully considered to maximize treatment outcomes.
Please note that this case study is entirely fictional and for illustrative purposes only. Real medical cases should be managed by healthcare professionals following established guidelines and protocols.